Brian Strem News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences

Kiora Pharmaceuticals, Inc. , will participate in two upcoming investor conferences that will be available to investors live with the replay available on-demand. On Wednesday May 22, at 3:00 pm.

Brian stremCalifornia newsfile corpKiora pharmaceuticalsKiora pharmaceuticals incWednesday mayEastern timeExecutive vice presidentMelissa toscaWebull corporate connect biotech investmentLytham partners springLytham partners

Kiora, Théa Open Innovation enter agreement for inherited retinal disease treatment

Kiora, Théa Open Innovation enter agreement for inherited retinal disease treatment
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Brian stremKiora pharmaceuticalsOpen innovation

Kiora Pharmaceuticals (KPRX) and Thea Open Innovation Enter Agreement to Develop and Commercialize KIO-301

Kiora Pharmaceuticals (KPRX) and Thea Open Innovation Enter Agreement to Develop and Commercialize KIO-301
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesBrian stremKiora pharmaceuticals incAmerican academy of ophthalmologyKiora pharmaceuticalsOpen innovationRetinitis pigmentosaAmerican academyRetinal ganglion cellsInvestor relations

Kiora Pharmaceuticals, Inc : Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront

Kiora Pharmaceuticals, Inc : Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesClermont ferrandBrian stremStefan klotterFrance newsfile corpKiora pharmaceuticalsKiora pharmaceuticals incAmerican academy of ophthalmologyOpen innovationRetinitis pigmentosaAmerican academyRetinal ganglion cellsInvestor relationsNorth africaSouth americaPrivate securities litigation reform act

Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clinical Development, Regulatory and Commercial Milestones, Plus Commercial Royalties

Kiora Pharmaceuticals, Inc. , a clinical-stage biotech company developing treatments for orphan retinal diseases, today announced that it has entered a strategic development and commercialization.

United statesClermont ferrandBrian stremAmerican academy of ophthalmologyKiora pharmaceuticals incKiora pharmaceuticalsFrance newsfile corpOpen innovationRetinitis pigmentosaAmerican academyRetinal ganglion cellsInvestor relationsNorth africaSouth americaPrivate securities litigation reform actAnnual report